Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report.
Lung adenocarcinoma, a prevalent form of non-small cell lung cancer, presents significant challenges due to its advanced stage at diagnosis and heterogeneity.
APA
Nimbalkar RG, Marne PA, et al. (2026). Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report.. Journal of Ayurveda and integrative medicine, 17(2), 101325. https://doi.org/10.1016/j.jaim.2026.101325
MLA
Nimbalkar RG, et al.. "Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report.." Journal of Ayurveda and integrative medicine, vol. 17, no. 2, 2026, pp. 101325.
PMID
41825247
Abstract
Lung adenocarcinoma, a prevalent form of non-small cell lung cancer, presents significant challenges due to its advanced stage at diagnosis and heterogeneity. This case report details the therapeutic journey of a 61-year-old female patient diagnosed with metastatic lung adenocarcinoma, managed through an integrative approach combining chemotherapy and Ayurvedic treatment. Conventional therapy consisted of carboplatin, pemetrexed, and geftinib, targeting both primary and metastatic sites. Concurrent Ayurvedic treatment was introduced to alleviate chemotherapy-related side effects and enhance the patient's quality of life. Over a 36 months period, the patient demonstrated minimal side effects and a near-complete regression of the primary lung lesions. This case highlights the potential of Ayurvedic medicine as an adjunct to chemotherapy, offering improvements in symptom management and overall patient well-being, without obstructing the chemotherapy efficacy.